Publications

Tofacitinib 5 mg twice daily provides clinically meaningful improvements in pain for patients with PsA.Reducing pain is a primary treatment concern for patients with PsA. As such, de Vlam, et al. set out to evaluate the time to pain improvement and the impact of baseline pain severity on pain response in patients with PsA receiving tofacitinib.Using data from the OPAL Broaden and OPAL Beyond trials, they discovered that clinically important improvements in pain were experienced by more patients, and more rapidly, with tofacitinib 5 mg twice daily and adalimumab 40 mg once every 2 weeks compared with placebo. In addition, this post hoc analysis showed that higher baseline pain was associated with faster pain improvements in those receiving tofacitinib 5 mg BID.